NCT06933095

Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 153 (estimated)
• Sponsor: University of Cincinnati · Academic / Other
• Sex: All
• Age: 55 Years – 82 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this placebo-controlled trial is to compare the effects of 24-weeks supplementation with LPC-DHA and TAG-DHA on cerebrospinal fluid and blood DHA levels, as well as biomarkers of central neurodegenerative and neurotrophic activity, in elderly adults experiencing early signs of cognitive/memory decline including those with mild cognitive impairment (MCI). Extant evidence supports our overarching hypothesis that LPC-DHA supplementation will be more effective than TAG-DHA for increasing central (CSF) DHA levels and improving biomarker profiles in elderly adults. To assess this hypothesis, the following aims are proposed: SPECIFIC AIM 1: To compare the effects of LPC-DHA and TAG-DHA supplementation on peripheral and CSF DHA levels in elderly adults experiencing early signs of cognitive/memory decline. SPECIFIC AIM 2: To compare the effects of LPC-DHA and TAG-DHA supplementation on neurotrophic and neurodegenerative biomarkers. Secondary Aim: To investigate whether changes in CSF DHA levels correlate with changes in objective measures of executive functioning and episodic memory performance.

Conditions

• Eldery People
• Cognitive Decline
• Memory Decline
• DHA CNS Delivery

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)	apsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)

Timeline

• Start date: 2024-09-15
• Primary completion: 2029-09-15
• Completion: 2029-09-15
• First posted: 2025-04-18
• Last updated: 2025-12-18

Locations

1 site across 1 country: United States